Ganapathi Bantwal

Ganapathi Bantwal

Auto-generated profile, based on publicly available information

Ganapathi Bantwal

Department of Endocrinology, St John’s Medical College Hospital, Bangalore, India

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2022 in JMIR Diabetes
Verified
Journal Article
Open access
RCRajeev Chawla
Rajeev Chawla
SJShalini Jaggi
Shalini Jaggi
AGAmit Gupta
Amit Gupta
GBGanapathi Bantwal
Ganapathi Bantwal
SPSuhas Patil
Suhas Patil
Background: Patients with type 2 diabetes mellitus (T2DM) having elevated levels of blood glucose and glycated hemoglobin (HbA1c) are at higher risk of macro- and microvascular complications. Nonetheless, the goal of achieving glycemic control cannot be met with the use of pharmacotherapy alone. The recent emergence of digital therapeutic tools has shown the possibility of improving the modifiable risk factors and self-management of diabetes. Objective: The aim of this study was to examine the clinical utility of a digital therapeutic intervention as an add-on therapy to achieve glycemic control in patients with T2DM. Methods: This was a 12-week prospective, single-arm digital intervention study in patients with T2DM receiving regular antidiabetic treatment. The eligibility criteria included male and female patients with HbA1c≥6.5%, functional English literacy, and a mobile phone capable of running the intervention app. Outcome measures of the study were mean changes in HbA1c, fasting blood glucose (FBG), postprandial blood glucose (PPBG), BMI, and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index at the end of 12 weeks. Results: A total of 128 participants completed the study period of 12 weeks. There were 54.7% (70/128) men and 45.3% (58/128) women with a mean age of 48.48 years (SD 10.27). At the end of 12 weeks, the mean change in HbA1c, FBG, PPBG, and BMI for the overall study population was –0.84% (P<.001), –8.39 mg/dl (P=.02), –14.97 mg/dl (P<.001), and –0.24 kg/m2 (P=.06), respectively. Among the participants showing improvement in the HbA1c value at the end of 12 weeks (responders), the mean change in HbA1c, FBG, PPBG, and BMI was –1.24% (P<.001), –12.42 mg/dl (P=.003), –21.45 mg/dl (P<.001), and –0.34 kg/m2 (P=.007), respectively. There was an increase in HOMA-IR values for the overall study population (0.54, P=.29). HbA1c response showed a significant association with a baseline HbA1c level ≥7.5%, no prior history of smoking, and no prior COVID-19 infection, as well as with higher levels of program engagement. Conclusions: A digital therapeutic intervention when used alongside standard medications significantly reduces HbA1c, FBG, and PPBG levels in patients with T2DM.

9 November 2021 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
SKSanjay Kalra
Sanjay Kalra
GBGanapathi Bantwal
Ganapathi Bantwal
NKNitin Kapoor
Nitin Kapoor
RSRakesh Sahay
Rakesh Sahay
SBSaptarshi Bhattacharya
Saptarshi Bhattacharya
ADAshok Kumar Das
Ashok Kumar Das
Type 2 diabetes mellitus (T2DM) is a chronic progressive disorder and is associated with significant morbidity and mortality. The concept of T2DM remission and the reversal of diabetic parameters to normal levels has been gaining momentum over the past years. T2DM remission is increasingly being recognized by various global guidelines. Multiple models have been developed and validated for quantifying the extent of remission achieved. Based on favorable clinical evidence, T2DM remission can be considered as the therapeutic goal in diabetes management and, in select cases, as an alternative to expensive treatment options, which can be burdensome as T2DM progresses. This narrative review discusses the available strategies, such as lifestyle interventions, physical activity, bariatric surgery, medical nutrition therapy, and non-insulin glucose-lowering medications, for achieving T2DM remission. Although the concept of T2DM remission has emerged as a real-world option, effective implementation in routine clinical practice may not be feasible until long-term studies prove the efficacy of different approaches in this regard.

23 May 2022 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
SJShashank R. Joshi
Shashank R. Joshi
RRRajesh Rajput
Rajesh Rajput
SCSubhankar Chowdhury
Subhankar Chowdhury
ASAwadhesh K. Singh
Awadhesh K. Singh
GBGanapathi Bantwal
Ganapathi Bantwal
VMViswanathan Mohan
Viswanathan Mohan

1 May 2021 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
EPElaina Pasangha
Elaina Pasangha
BGBelinda George
Belinda George
JVJayalakshmi Vallamkondu
Jayalakshmi Vallamkondu
PDPadmini Devi
Padmini Devi
VAVageesh Ayyar
Vageesh Ayyar
GBGanapathi Bantwal
Ganapathi Bantwal

22 February 2023 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
SKSanjay Kalra
Sanjay Kalra
JJJubbin Jacob
Jubbin Jacob
AUA. G. Unnikrishnan
A. G. Unnikrishnan
GBGanapathi Bantwal
Ganapathi Bantwal
ASAbhay Sahoo
Abhay Sahoo
KKKapil Kochhar
Kapil Kochhar
Male hypogonadism (MH) is a clinical and biochemical syndrome caused by inadequate synthesis of testosterone. Untreated MH can result in long-term effects, including metabolic, musculoskeletal, mood-related, and reproductive dysfunction. Among Indian men above 40years of age, the prevalence of MH is 2029. Among men with type 2 diabetes mellitus, 20.7 are found to have hypogonadism. However, due to suboptimal patient-physician communication, MH remains heavily underdiagnosed. For patients with confirmed hypogonadism (either primary or secondary testicular failure), testosterone replacement therapy (TRT) is recommended. Although various formulations exist, optimal TRT remains a considerable challenge as patients often need individually tailored therapeutic strategies. Other challenges include the absence of standardized guidelines on MH for the Indian population, inadequate physician education on MH diagnosis and referral to endocrinologists, and a lack of patient awareness of the long-term effects of MH in relation to comorbidities. Five nationwide advisory board meetings were convened to garner expert opinions on diagnosis, investigations, and available treatment options for MH, as well as the need for a person-centered approach. Experts opinions have been formulated into a consensus document with the aim of improving the screening, diagnosis, and therapy of men living with hypogonadism.

30 April 2024 in Folia Medica
Verified
Journal Article
Open access
PDF file
GVGanesh Viswanathan
Ganesh Viswanathan
VMVivek Mathew
Vivek Mathew
MJMallikarjuna Jeeragi
Mallikarjuna Jeeragi
BGBelinda George
Belinda George
GBGanapathi Bantwal
Ganapathi Bantwal
JMJohn Michael
John Michael
Introduction: Primary hyperparathyroidism (PHPT) is a common endocrine disease with a variable presentation. There is a recent increase in the number of asymptomatic cases due to the use of multichannel automated analyzers. Aim: To analyze the changing trend of PHPT patients from South India. Materials and methods: We collected the data on clinical presentation, biochemistry, radiological features, and operative findings of patients with PHPT treated in our hospital over a period of six years and looked at the differences between symptomatic and asymptomatic PHPT. Results: Our study included 80 patients. A significant proportion (~41%; n=33) of the patients were asymptomatic. Fifty-seven percent of asymptomatic patients were females. Mean age at presentation of asymptomatic patients was 50.58 (±14.67) compared to 47.28 (±14.78) for the symptomatic group, which was not statistically significant (p=0.34). The mean levels of serum calcium, phosphorous, 25(OH)D, iPTH, and 24-hour urinary calcium in symptomatic vs. asymptomatic patients were 12.47 (±2.26) mg/dl vs. 12.27 (±1.82) mg/dl (p=0.70), 2.59 (±0.74) mg/dl vs. 2.38 (±0.77) mg/dl (p=0.27), 12 (±1.2) ng/ml vs. 10.85 (±1) ng/ml (p=0.78), 1212.5 pg/ml vs. 678.5 pg/ml (p=0.31), and 292.6 mg/day vs. 262 mg/day (p=0.64), respectively. When Ca and gland weight were compared with variations in the iPTH levels, there was a significant positive correlation with PTH >600 pg/ml (p=0.001) with no between-group differences. The adenoma weight increased by 0.5291 mg for every unit increase in iPTH in the entire cohort, with no between-group differences (p=0.52). Conclusion: Asymptomatic hyperparathyroidism is increasingly being identified in clinical practice and constitutes a significant proportion of primary hyperparathyroidism. Though asymptomatic PHPT is expected to be milder, such a difference in presentation was not obvious in our study.